169 related articles for article (PubMed ID: 27283831)
21. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
22. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
23. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
24. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
25. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles.
Taghdisi SM; Danesh NM; Lavaee P; Emrani AS; Hassanabad KY; Ramezani M; Abnous K
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():753-61. PubMed ID: 26838906
[TBL] [Abstract][Full Text] [Related]
26. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
27. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
[TBL] [Abstract][Full Text] [Related]
28. Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release.
Chida T; Miura Y; Cabral H; Nomoto T; Kataoka K; Nishiyama N
J Control Release; 2018 Dec; 292():130-140. PubMed ID: 30391405
[TBL] [Abstract][Full Text] [Related]
29. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.
Zhou W; Zhou Y; Wu J; Liu Z; Zhao H; Liu J; Ding J
J Drug Target; 2014 Jan; 22(1):57-66. PubMed ID: 24156476
[TBL] [Abstract][Full Text] [Related]
30. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery.
Chang LC; Wu SC; Tsai JW; Yu TJ; Tsai TR
Int J Pharm; 2009 Jul; 376(1-2):195-203. PubMed ID: 19439169
[TBL] [Abstract][Full Text] [Related]
31. Self-Assembled Hybrids of Fluorescent Carbon Dots and PAMAM Dendrimers for Epirubicin Delivery and Intracellular Imaging.
Matai I; Sachdev A; Gopinath P
ACS Appl Mater Interfaces; 2015 Jun; 7(21):11423-35. PubMed ID: 25946165
[TBL] [Abstract][Full Text] [Related]
32. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
Ozkan A; Ayhan A; Fiskin K
Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
[TBL] [Abstract][Full Text] [Related]
33. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
[TBL] [Abstract][Full Text] [Related]
34. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
35. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
36. Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells.
Li LL; Yin Q; Cheng J; Lu Y
Adv Healthc Mater; 2012 Sep; 1(5):567-72. PubMed ID: 23184791
[TBL] [Abstract][Full Text] [Related]
37. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers.
Di-Wen S; Pan GZ; Hao L; Zhang J; Xue QZ; Wang P; Yuan QZ
Int J Pharm; 2016 Mar; 500(1-2):54-61. PubMed ID: 26748365
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
[TBL] [Abstract][Full Text] [Related]
39. A multi-storey DNA nanostructure containing doxorubicin and AS1411 aptamer for targeting breast cancer cells.
Yaghoobi E; Zavvar T; Ramezani M; Alibolandi M; Rahimzadeh Oskuei S; Zahiri M; Alinezhad Nameghi M; Abnous K; Taghdisi SM
J Drug Target; 2022 Dec; 30(10):1106-1112. PubMed ID: 35736221
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of AS1411 and FOXM1 aptamers.
Abnous K; Danesh NM; Ramezani M; Charbgoo F; Bahreyni A; Taghdisi SM
Expert Opin Drug Deliv; 2018 Nov; 15(11):1045-1052. PubMed ID: 30269603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
